Ariad Shares Rise Amid Speculation of Potential Buyout

Ariad Pharmaceuticals Inc., a takeover target last year before talks failed over the price, rose the most in a month on speculation that the drugmaker may be a buyout candidate yet again.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.